Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07015333

Enrollment

Registered

2025-06-11

Start date

2020-03-01

Completion date

2024-12-01

Last updated

2025-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Squamous Cell Carcinoma (OSCC)

Brief summary

Chart review of records of patients treated for betel nut-induced oral cancer with pembrolizumab and cetuximab.

Interventions

DRUGpembrolizumab and cetuximab

Treatment of betel nut-induced oral cancer with pembrolizumab and cetuximab

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Advanced betel nut-induced oral cancer

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Objective Response Rate (ORR)	From date first treatment received until 3 months later	Assessed by clinical measurement of largest tumor size

Countries

Northern Mariana Islands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026